Wolfe Research analyst Alexandria Hammond initiated coverage of Johnson & Johnson (JNJ) with an Outperform rating and $190 price target The firm expects growth names and/or “dream the dream” names to be the winners looking to 2025 and outside of Mounjaro/Zepbound from Lilly (LLY), the firm sees J&J’s Pharma growth drivers of JNJ-2113, Tremfya, nipocalimab, Carvykti, and Drazalex Faspro as “best-in-class.” Moreover, even with Stelara facing loss-of-exclusivity headwinds, Wolfe still forecasts J&J’s revenue growing at least 3%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson initiated with an Outperform at Wolfe Research
- Johnson & Johnson announces results from analyses of Phase 2 DAHLIAS study
- Charter to acquire Liberty Broadband, Spotify reports Q3 beat: Morning Buzz
- J&J sues government agency over payment terms for 340B hospitals, STAT says
- Johnson & Johnson MedTech receives IDE approval for Ottava system